1 Min Read
June 14 (Reuters) - EMEA
* Janssen presents long term phase 3 efficacy and safety data of Sirukumab in rheumatoid arthritis patients who had an inadequate response and/or who were intolerant to anti-tnfs
* Janssen EMEA says " long-term efficacy of sirukumab as shown in sirround-t study is encouraging"
* Janssen EMEA- investigators reported treatment with Sirukumab consistently increased levels of haemoglobin in adult patients with moderately to severely active RA
* Janssen EMEA says patients receiving sirukumab demonstrated clinically "meaningful" improvements from baseline through week 52 in quality of life measures Source text for Eikon: Further company coverage: